Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation

J Thorac Oncol. 2019 Oct;14(10):e220-e221. doi: 10.1016/j.jtho.2019.05.023.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Afatinib / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cetuximab / administration & dosage
  • ErbB Receptors / genetics
  • Exons*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Mutagenesis, Insertional*
  • Prognosis

Substances

  • Afatinib
  • EGFR protein, human
  • ErbB Receptors
  • Cetuximab